Interferon gamma

Oncotelic Therapeutics Announces Clinical Linkage of TGFB2 and IFNGR2 in Pediatric DMG Patients

Retrieved on: 
Tuesday, January 16, 2024
Mortality, Neoplasm, Patient, CD163, JAK1, Therapy, Research, Survival, Cancer, CD86, TGF-B2, OTCQB, STAT1, APC, HR, CD14, TGFB2, Interferon gamma, Messenger, TME, DMG, Glioma, Vaccine

We hope that sharing these findings from our research team will contribute to the eradication of cancer," stated Dr. Vuong Trieu, CEO and Chairman of Oncotelic.

Key Points: 
  • We hope that sharing these findings from our research team will contribute to the eradication of cancer," stated Dr. Vuong Trieu, CEO and Chairman of Oncotelic.
  • IFNGR2 is a critical component of the IFN-γ signaling pathway, playing a significant role in mediating the immune system's defense against cancer.
  • The expression levels of IFNGR2 and TGFB2 (1.51-fold increase (p = 0.002) and 1.58-fold increase (p = 5.5 × 10−4), respectively) were significantly upregulated in pbDMG tumors compared with normal brainstem/pons samples.
  • Worse survival outcomes in pbDMG patients when comparing high versus low TGFB2 levels in the context of low IFNGR2 levels suggest that the abrogation of the TGFB2 mRNA expression in the immunologically cold tumor microenvironment can be used to treat pbDMG patients.

INmune Bio Inc. Demonstrates that INB03 Enhances the Uptake of Trastuzumab Deruxtecan in HER2+ Breast Cancer with MUC4 Expression in Poster Presented at San Antonio Breast Cancer Symposium

Retrieved on: 
Wednesday, November 29, 2023
Immunotherapy, Daiichi Sankyo, TNF, Neoplasm, Tumor microenvironment, TME, HER2, Woman, Breast cancer, TAM, Disease, Interferon gamma, MUC4, Poster, ADC, Vaccine

Boca Raton, Florida, Nov. 29, 2023 (GLOBE NEWSWIRE) --  INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, is presenting data on the use of INB03, a dominant-negative TNF inhibitor of soluble TNF (sTNF) in the treatment of high-risk MUC4 expressing HER2. Roxana Schillaci, Ph.D., of Instituto de Biología y Medicina Experimental in Buenos Aries, Argentina, will present her work at the 46th annual San Antonio Breast Cancer Symposium, which runs from December 5 to 9.

Key Points: 
  • Roxana Schillaci, Ph.D., of Instituto de Biología y Medicina Experimental in Buenos Aries, Argentina, will present her work at the 46th annual San Antonio Breast Cancer Symposium, which runs from December 5 to 9.
  • “This work demonstrates another way that MUC4 expression causes resistance to HER2-targeted immunotherapy in women with resistant breast cancer," said Dr. Schillaci, who is also associated with CONICET and is senior author of this work.
  • INB03 decreases MUC4 expression on the surface of the breast cancer cells increasing the ability of the antibody to bind to the HER2 target on the cancer cell.
  • Resistance to trastuzumab immunotherapy can be predicted prospectively based on simple immunohistochemistry stains detecting tumor expression of MUC4.

Molecular Partners Presents Updated Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 SITC Annual Meeting

Retrieved on: 
Friday, November 3, 2023
Patient, Biomarker, FAP, Therapy, Molecular Partners, Poster, SITC, Immunotherapy, Interferon gamma, Annual general meeting, Serum, Tumor microenvironment, CXCL10, Safety, Society, DARPin, CMO, TME, CD40, Medical imaging, Pharmaceutical industry, Vaccine, CONCORD

MP0317 is a CD40 agonist designed to activate immune cells specifically within the tumor microenvironment (TME) by anchoring to fibroblast activation protein (FAP).

Key Points: 
  • MP0317 is a CD40 agonist designed to activate immune cells specifically within the tumor microenvironment (TME) by anchoring to fibroblast activation protein (FAP).
  • “The encouraging results presented at SITC provide clinical evidence of MP0317-induced, tumor-targeted CD40 activation.
  • The positive results of this fully enrolled Phase 1 study in patients with refractory/relapsed tumors support continued clinical evaluation of MP0317 and potential investigation in combination studies.
  • Patients received MP0317 at doses of 0.03–10 mg/kg in every-3-weeks (Q3W) or weekly (Q1W) schedules (data cut-off 10 October 2023).

Antiverse and GlobalBio, Inc. Extend Collaboration to Advance Antibody Cancer Therapeutics

Retrieved on: 
Monday, October 16, 2023
Technology, Research, Clinical Trials, Biotechnology, Health, Pharmaceutical, Science, Artificial Intelligence, Oncology, Multimedia, Cancer, Antibody, Therapy, PD-L1, Toxicity, Interferon gamma, D13, Jurkat cells, Library, Human, PD-1, Vaccine, Palladium

Antiverse Ltd (Antiverse), a biotechnology company developing a computational antibody drug discovery platform, and GlobalBio, Inc. (GlobalBio), an antibody engineering company developing methods to engineer improved and more developable therapeutic antibodies, today announced they will be extending their collaboration to advance immune checkpoint inhibitors in cancer therapy.

Key Points: 
  • Antiverse Ltd (Antiverse), a biotechnology company developing a computational antibody drug discovery platform, and GlobalBio, Inc. (GlobalBio), an antibody engineering company developing methods to engineer improved and more developable therapeutic antibodies, today announced they will be extending their collaboration to advance immune checkpoint inhibitors in cancer therapy.
  • The initial collaboration successfully resulted in the generation of a panel of anti-PD-1 antibodies with diverse binding and functional profiles, with two candidates from this panel now entering preclinical development.
  • Through these types of innovative collaborations, Antiverse plays a vital role in accelerating the identification and development of novel antibody therapeutics for cancer, reducing drug discovery timelines and costs.
  • We aim to continue to ‘open up’ the druggable antibody space.”
    Dr Juan Carlos Almagro, Founder and CEO at GlobalBio, Inc., added: “Antiverse’s antibody discovery platform complements our libraries and antibody engineering capabilities well.

Vaccitech Reports Second Quarter 2023 Financial Results and Recent Corporate Developments

Retrieved on: 
Thursday, August 10, 2023
Infection, EASL, Interferon gamma, PSA, Prostate cancer, Clinical trial, American depositary receipt, Cancer, Woman, Research, Autoimmunity, AstraZeneca, Hepatitis B, Public expenditure, Arbutus, Retirement, Investigational New Drug, ELISpot, Data, Patient, Laboratory, Immune system, Non-carious cervical lesions, HPV, Depreciation, European Association for the Study of the Liver, Vaccitech, HBV, Oxford University Innovation, IND, Disease, Conference, Safety, OUI, Nivolumab, Vaccine, Pharmaceutical industry, Clothing, Liver, HBsAg

Data included results for 42 women at Day 35, 7 days after the last dose of VTP-200.

Key Points: 
  • Data included results for 42 women at Day 35, 7 days after the last dose of VTP-200.
  • The final dataset, including data on clearance of infection and cervical lesions at 12 months post-treatment, is expected in the second quarter of 2024.
  • Revenue: Revenue consisted of $0.3 million in the second quarter of 2023 compared to $0.5 million in the first quarter of 2023.
  • Research and development expenses: Research and development expenses were $13.5 million in the second quarter of 2023 compared to $9.8 million in the first quarter of 2023, showing increased spend due to phasing of clinical and pre-clinical trials.

Corvus Pharmaceuticals Presents New Ciforadenant Preclinical Data at the 2nd JCA-AACR Precision Cancer Medicine International Conference

Retrieved on: 
Thursday, June 29, 2023
Myelocyte, Interferon gamma, Clinical trial, CXCL10, Cancer, IL-6, Tumor necrosis factor, Research, ICB, Publication, American Association for Cancer Research, Kidney cancer, ISCB Senior Scientist Award, Poster, Neoplasm, Gene, Tumor microenvironment, Conference, Japanese Cancer Association, Pharmaceutical industry, Vaccine, Medical imaging, Corvus

BURLINGAME, Calif., June 29, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced new preclinical data for ciforadenant, the Company’s adenosine 2A receptor inhibitor, highlighting its mechanism of action and synergy with immune checkpoint inhibitors via combination with anti-CTLA-4 and anti-PD-1 therapies. The data is being presented in a poster at the 2nd Japanese Cancer Association and American Association for Cancer Research (JCA-AACR) Precision Cancer Medicine International Conference, which is taking place June 28-30, 2023 in Kyoto, Japan.

Key Points: 
  • The data is being presented in a poster at the 2nd Japanese Cancer Association and American Association for Cancer Research (JCA-AACR) Precision Cancer Medicine International Conference, which is taking place June 28-30, 2023 in Kyoto, Japan.
  • “We are exploring this combination in a Phase 1b/2 clinical trial that is being led by the Kidney Cancer Research Consortium.
  • Ciforadenant treatment increased production of chemokine CXCL10, a ligand for recruitment of CXCR3+ Th1 helper cells into the tumor.
  • The combination of ciforadenant with ICB promoted the production of several proinflammatory cytokines such as IL-6, TNFa, and IFNg.

TriSalus Life Sciences Presents Additional Data for SD-101 Delivered by the Proprietary PEDD™ Method with the TriNav™ Device for Uveal Melanoma Liver Metastases at the ASCO 2023 Annual Meeting

Retrieved on: 
Monday, June 12, 2023
Oncology, Medical Devices, Health, Research, Science, Biotechnology, Drug, CT, Interferon gamma, Liver disease, Serum, American Society of Clinical Oncology, Business, Immunotherapy, Uveal melanoma, MTAC, Cell, Trial of the century, ASCO, MDSC, Patient, Mass, Blood, Annual general meeting, Mass General Brigham, FACS, Liver, Neoplasm, Therapy, Society, Medtech, Medical imaging, Vaccine, Pharmaceutical industry, MD

PERIO-01 is evaluating whether this platform approach can improve the performance of systemic checkpoint inhibitors in patients with UMLM.

Key Points: 
  • PERIO-01 is evaluating whether this platform approach can improve the performance of systemic checkpoint inhibitors in patients with UMLM.
  • PERIO-01 is an open-label, first-in-human Phase 1 trial of SD-101, administered by hepatic arterial infusion with TriNav using PEDD in UMLM.
  • The study consists of dose-escalation cohorts of SD-101 (2, 4, or 8 mg) alone or with immune checkpoint inhibition.
  • The data were also selected for presentation at the Developmental Therapeutics - Immunotherapy Poster Discussion Session on June 3, 2023 at 3:00pm CT.

Cellectis Showcased Preclinical Data at an Oral Presentation and Two Poster Presentations at the 29th International Society for Cell & Gene Therapy (ISCT 2023) Annual Event

Retrieved on: 
Monday, June 5, 2023
Graft-versus-host disease, HD, Antigen, DNA, BP, TRAC, HSPC, Euronext Growth, Interferon gamma, UGI, CD19, Red blood cell, ISCT, Lymphoid leukemia, CD20, Neoplasm, Thymine, Patient derived xenograft, Survival, Gene editing, Bone marrow, CD52, CD22, Deamination, Toxicity, Cell, Stem cell, PDX, CAR, Patient, Risk, Engineering, International Society, Knowledge, HBB, TALEN, TC, Phenotype, Vaccine, Online shopping, Cosmetics, HBSS, Cellectis, Cytosine

The therapeutic options after CAR T-cell relapses are limited, emphasizing the need to develop novel therapies to improve current survival rates.

Key Points: 
  • The therapeutic options after CAR T-cell relapses are limited, emphasizing the need to develop novel therapies to improve current survival rates.
  • UCART20x22 is Cellectis’ first dual-targeting, allogeneic cell therapy product candidate targeting CD20 and CD22, to address the current challenges in the treatment of B-cell malignancies.
  • The oral presentation highlighted the following preclinical data:
    Robust in vitro and in vivo cytolytic activity against tumors expressing different antigen combinations.
  • The oral presentation is available on Cellectis’ website: https://www.cellectis.com/en/investors/scientific-presentations/
    Sickle cell disease stems from a single point mutation in the HBB gene which results in sickle hemoglobin.

Vaccitech Presents Interim Data from Phase 1b/2 Study of VTP-200 at 35th Annual International Papillomavirus Conference (IPVC) Highlighting Favorable Tolerability and Immunogenicity Profile

Retrieved on: 
Monday, April 17, 2023
Infection, Interferon gamma, Clinical trial, Cancer, Woman, CMO, OXFORD, Șaeș, Human papillomavirus infection, APOLLO, E2, CD8, ELISpot, E6, Immune system, Non-carious cervical lesions, HPV, Poster, CD4, Conference, Safety, Vaccine, Vaccitech

The APOLLO trial (also known as HPV001) is a fully enrolled Phase 1b/2 study of VTP-200 in women with low-grade cervical lesions associated with persistent human papillomavirus (HPV) infection.

Key Points: 
  • The APOLLO trial (also known as HPV001) is a fully enrolled Phase 1b/2 study of VTP-200 in women with low-grade cervical lesions associated with persistent human papillomavirus (HPV) infection.
  • “The safety and immunogenicity data presented at IPVC shows the potential of VTP-200 in treating persistent high-risk HPV (hrHPV) infections.
  • Currently, women with persistent HPV infections have no treatment options until they develop high grade lesions,” said Meg Marshall, CMO of Vaccitech.
  • In addition, intracellular cytokine staining data from the active groups showed both CD4 and CD8 responses.

Corvus Pharmaceuticals Presents New CPI-818 Data Demonstrating the Potential of ITK Inhibition as a Treatment for Solid and Hematologic Cancers at the American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
Monday, April 17, 2023
Antigen, T helper cell, AACR, Interferon gamma, TCL, Perforin-1, TNF, ALC, Neoplasm, Infection, ITK, Clinical trial, American Association for Cancer Research, NK, IL10, T-cell lymphoma, Cell, Publication, Immunotherapy, Colon, IL4, Hematological Cancer Research Investment and Education Act, Downregulation and upregulation, CD8, Animal, Patient, Enrollment, Melanoma, Immune system, Annual general meeting, IL17, Growth, Poster, CD4, IL9, Lymphocyte, Cytokine, FDA, ACL, B16, IL5, Tumor microenvironment, Safety, Vaccine, Pharmaceutical industry, Corvus

BURLINGAME, Calif., April 17, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced new data for CPI-818, the Company’s ITK inhibitor, demonstrating its potential to treat a variety of solid and hematological cancers based on a novel immunotherapy mechanism of action. The data will be presented today in a poster at the American Association for Cancer Research (AACR) Annual Meeting, which is taking place April 14-19, 2023 in Orlando, FL.

Key Points: 
  • The data will be presented today in a poster at the American Association for Cancer Research (AACR) Annual Meeting, which is taking place April 14-19, 2023 in Orlando, FL.
  • “CPI-818 inhibited tumor growth in five different tumor models including colon, renal and melanoma cancers, and in both T and B cell lymphomas.
  • These properties are a result of the myriad of functions that ITK plays in T cell biology.
  • The triplet combination led to complete tumor elimination in 19 of 20 animals with established CT26 colon cancer tumors.